Science AI Journal
Medicine · Research topic

Open research questions in Chemotherapy-induced cardiotoxicity and mitigation

91 unresolved questions extracted from the limitations and future-work sections of 235 Chemotherapy-induced cardiotoxicity and mitigation papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • Long-term cardiac monitoring data for neratinib remain sparse, - Formal QT analyses from early-phase trials are limited, - Real-world data highlight gaps between guidelines and clinical practice

    Cardiovascular Toxicity of Novel HER2-Targeted Agents and Multikinase Inhibitors in Oncology: From Mechanisms to Real-World Clinical Evidence · 2026 · DOI

  • Longitudinal monitoring of patients with vascular comorbidities, - Assessment of cardiac effects of pyrotinib, - Investigation of cardio-oncology in bridging oncologic efficacy with cardiac safety

    Cardiovascular Toxicity of Novel HER2-Targeted Agents and Multikinase Inhibitors in Oncology: From Mechanisms to Real-World Clinical Evidence · 2026 · DOI

  • The paper identifies a gap in the understanding of hypertension-related mortality among cancer patients, particularly in the context of shared risk factors and the effects of cancer treatment on hypertension. The study highlights the need for effective management of comorbid hypertension as cancer survival rates improve.

    Excess hypertension-related mortality among cancer patients in the United States: a SEER-based study · 2026 · DOI

  • Future research should investigate patient-level risk fac- tors, comorbidities, treatment patterns, and socioeconomic determinants to reduce hypertension mortality and improve long-term outcomes in cancer survivors.

    Excess hypertension-related mortality among cancer patients in the United States: a SEER-based study · 2026 · DOI

  • DISCUSSION: This population-based study showed that patients with cancer had higher risks of mortality after stroke and MI, with substantial variations by cancer type, although cause-specific mortality data were lacking.

    Association of a Cancer Diagnosis and Mortality After Ischemic and Hemorrhagic Stroke and Myocardial Infarction · 2026 · DOI

  • However, whether cancer affects mortality outcomes after stroke and myocardial infarction (MI) remains unclear.

    Association of a Cancer Diagnosis and Mortality After Ischemic and Hemorrhagic Stroke and Myocardial Infarction · 2026 · DOI

  • Future research should focus on validating clinical biomarker panels and optimizing targeted delivery systems.

    MicroRNAs in anthracycline cardiotoxicity: biomarkers, mechanisms, and therapeutic advances · 2025 · DOI

  • This dual-phase presentation and subsequent successful rechallenge with bolus-based 5-FU chemotherapy have not been previously reported.

    Case Report: Coronary vasospasm precipitating STEMI and polymorphic ventricular tachycardia—a case of cardiotoxicity from 5-FU based chemotherapy in a 41-year-old woman · 2025 · DOI

  • While ACE inhibitors and angiotensin receptor blockers (ARBs) have demonstrated modest cardioprotective effects, the efficacy of newer heart failure therapies remains underexplored.

    From bench to bedside: investigating SGLT2 inhibitors as a novel strategy against chemotherapy-induced cardiomyopathy · 2025 · DOI

  • In contrast, ACE inhibitors and β-blockers have shown variable efficacy during chemotherapy, with inconsistent findings across studies.

    From bench to bedside: investigating SGLT2 inhibitors as a novel strategy against chemotherapy-induced cardiomyopathy · 2025 · DOI

  • The mechanisms underlying DOX-induced cardiotoxicity (DIC) remain incompletely understood.

    Doxorubicin induces cardiotoxicity by enhancing autophagy via mTOR signaling in hiPSC- and hESC-derived cardiomyocytes · 2025 · DOI

  • The exact mechanisms of DOX-induced cardiotoxicity remain unclear, requiring further investigation.

    Metabolomic profiling and biomarker identification for early detection and therapeutic targeting of doxorubicin-induced cardiotoxicity · 2025 · DOI

  • Despite encouraging progress, standardized treatment protocols and robust long-term outcome data remain limited.

    Cancer-Induced Cardiac Dysfunction: Mechanisms, Diagnostics, and Emerging Therapeutics in the Era of Onco-Cardiology · 2025 · DOI

  • However, the ET effects on cardiac function and glucose metabolism in DOX-treated breast cancer models remain unclear.

    Exercise training partly ameliorates cardiac dysfunction in mice during doxorubicin treatment of breast cancer · 2025 · DOI

  • Future studies are needed to confirm these findings and investigate interventions to improve patient outcomes, including personalized cancer screening.

    Cardiovascular Disease and Breast Cancer Stage at Diagnosis · 2025 · DOI

  • Additionally, we propose further studies on using statins for the prevention of cardiovascular disease in anticancer treatment.

    Statins in Mitigating Anticancer Treatment-Related Cardiovascular Disease · 2024 · DOI

  • However, direct evidence proving that statins can mitigate CAR-T cell therapy-induced cardiotoxicity is still lacking.

    Statins in Mitigating Anticancer Treatment-Related Cardiovascular Disease · 2024 · DOI

  • However, the elaborate mechanisms of calycosin treating AIC remain to be unrevealed.

    Exploring the effects of calycosin on anthracycline-induced cardiotoxicity: a network pharmacology, molecular docking, and experimental study · 2024 · DOI

  • Further studies on dexrazoxane are warranted to confirm whether its role in reducing cardiac toxic effects is maintained long term.

    Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children · 2024 · DOI

  • There is a need to understand the effects of doxorubicin on skeletal muscle in cancer patients. There is a need to identify effective interventions to prevent muscle wasting in cancer patients.

    Potential biomarkers and preventative interventions for muscle wasting in adolescent and young adults with cancer: A translational study · 2026 · DOI

  • Several limitations warrant considered. First, the preclinical model uses a single age and sex (4-week-old female mice) to approximate an adolescent stage and does not capture the full age- and sex-related heterogeneity within the AYA population. Second, the miRNA analysis was conducted on a small sample size due to collection time point feasibility challenges (n=16). While our targeted analysis of miR-133b, miR-206, and miR-126 revealed consistent reductions post-Dox that were mitigated by exercise, comprehensive miRNA sequencing could further elucidate broader expression profiles altered by Dox therapy and exercise interventions. Such an approach might identify novel candidates involved in mitophagy, autophagy, or vascular repair pathways, providing deeper insights into the molecular mechanisms of Dox-induced muscle wasting and exercise-mediated protection. Future studies incorporating miRNA sequencing in both preclinical models and larger AYA cohorts will be essential to validate and expand these findings. Third, given that the present study was not designed to elucidate determinates of physical activity such as tumor burden or location, the influence of tumor burden and location should be considered potential confounding factors and controlled for in future larger scale investigations. Fourth, as the study focus was on AYAs diagnosed with sarcoma and the chemotherapeutic treatment doxorubicin, these findings may not be generalizable to AYAs with other cancer types or ARTICLE IN PRESS ARTICLE IN PRESS ACCEPTED MANUSCRIPT receiving different chemotherapies. Moreover, skeletal muscle loss may vary based on tumor location and associated physical limitations which may impact activity levels. Although CT imaging fields containing the presence of local tumor were not used in the current study, we did not evaluate the influence of variable peripheral tumor location on skeletal muscle loss. Future studies should aim to address these gaps. Fifth, the translational gap between mouse treadmill exercise and human physical activity should be carefully considered. Additionally, the importance of considering sex as a biological variable in biomedical research has been emphasized in recent guidelines (62). Given that the present study utilized only female mice in accordance with our previously published model (8), future studies should investigate whether these findings are also seen in males. Sixth, individual skeletal muscle wet weights and cross-sectional area were not measured, as the study was designed to focus on histologic, ultrastructural, and molecular indicators of muscle injury.

    Potential biomarkers and preventative interventions for muscle wasting in adolescent and young adults with cancer: A translational study · 2026 · DOI

  • The vast majority of existing literature comprises preclinical studies, which have limitations. The study acknowledges the need for further research to establish the efficacy and safety of traditional Chinese medicine in preventing and treating anthracycline-induced cardiac toxicity.

    Research Progress on Integrated Traditional Chinese and Western Medicine for the Prevention and Treatment of Anthracycline-Induced Cardiac Toxicity: A Multi-Target Regulatory Network and Clinical Translation Perspective · 2026 · DOI

  • The current state of research on anthracycline-induced cardiac toxicity has limitations, and there is a need for further research to establish the efficacy and safety of traditional Chinese medicine. The study identifies a gap in the understanding of the mechanisms of action of various compound formulas and their potential therapeutic applications.

    Research Progress on Integrated Traditional Chinese and Western Medicine for the Prevention and Treatment of Anthracycline-Induced Cardiac Toxicity: A Multi-Target Regulatory Network and Clinical Translation Perspective · 2026 · DOI

  • Doxorubicin-induced cardiotoxicity is a leading cause of mortality among cancer patients. Oxidative stress is a central pathogenic mechanism. There is a need for effective prevention and treatment strategies.

    Sacubitril valsartan combined with bisoprolol reduces doxorubicin-induced cardiotoxicity in rats by attenuating oxidative stress · 2026 · DOI

  • The mechanisms behind VEGF inhibitor-induced hypertension are not fully understood. There is a need for more effective strategies for managing therapy-induced hypertension. The potential of hypertension as a biomarker of therapeutic efficacy in certain cancer treatments requires further investigation.

    Onco-hypertension: hypertension induced by VEGF pathway inhibition · 2026 · DOI

Most-cited papers in Chemotherapy-induced cardiotoxicity and mitigation

Most recent work

Find a gap in your own Chemotherapy-induced cardiotoxicity and mitigation sub-topic

This page shows what the Chemotherapy-induced cardiotoxicity and mitigation literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Medicine

Artificial Intelligence in Healthcare and Education
2,044 open questions
Substance Abuse Treatment and Outcomes
1,964 open questions
Smoking Behavior and Cessation
990 open questions
Dementia and Cognitive Impairment Research
974 open questions
Innovations in Medical Education
960 open questions
Physical Activity and Health
923 open questions
Attention Deficit Hyperactivity Disorder
839 open questions
Schizophrenia research and treatment
709 open questions
91 open questions have been extracted from the limitations and future-work passages of 235 Chemotherapy-induced cardiotoxicity and mitigation papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.